Incorporating anti-VEGF pathway therapy as a continuum of care in metastatic colorectal cancer (Q38392336)

2 September 2017

1 reference

title

Incorporating anti-VEGF pathway therapy as a continuum of care in metastatic colorectal cancer (English)

1 reference

2 September 2017

1 reference

8

1 reference

2 September 2017

9

1 reference

2 September 2017

author name string

Konstantinos Papadimitriou

1

1 reference

2 September 2017

Christian Rolfo

2

1 reference

2 September 2017

Elien Dewaele

3

1 reference

2 September 2017

Mick Van De Wiel

4

1 reference

2 September 2017

Jan Van den Brande

5

1 reference

2 September 2017

Sevilay Altintas

6

1 reference

2 September 2017

Manon Huizing

7

1 reference

2 September 2017

publication date

1 April 2015

1 reference

Current Treatment Options in Oncology

2 September 2017

published in

1 reference

2 September 2017

volume

16

1 reference

2 September 2017

issue

4

1 reference

2 September 2017

page(s)

18

1 reference

The continuum of care: a paradigm for the management of metastatic colorectal cancer

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0333-9

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0333-9

First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0333-9

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0333-9

Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0333-9

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0333-9

Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0333-9

Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0333-9

Reinduction therapy with the same cytostatic regimen in patients with advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0333-9

Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0333-9

OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0333-9

Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0333-9

Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0333-9

Impact of 5-fluorouracil rechallenge on subsequent response and survival in advanced colorectal cancer: pooled analysis from three consecutive randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0333-9

Rechallenge with oxaliplatin and fluoropyrimidine for metastatic colorectal carcinoma after prior therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0333-9

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0333-9

Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0333-9

Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0333-9

Treatment of Colorectal Cancer with and without Bevacizumab: A Phase III Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0333-9

Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0333-9

Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0333-9

Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0333-9

Bevacizumab in association with de Gramont 5-fluorouracil/folinic acid in patients with oxaliplatin-, irinotecan-, and cetuximab-refractory colorectal cancer: a single-center phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0333-9

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0333-9

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0333-9

Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0333-9

A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0333-9

Survival outcomes of bevacizumab beyond progression in metastatic colorectal cancer patients treated in US community oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0333-9

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0333-9

Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0333-9

Resectability and outcome with anti-EGFR agents in patients with KRAS wild-type colorectal liver-limited metastases: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0333-9

Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0333-9

Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0333-9

Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0333-9

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0333-9

Managing advanced colorectal cancer: have we reached the PEAK with current therapies?

21 January 2018

1 reference

12 December 2020

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

1 reference

12 December 2020

Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study

1 reference

12 December 2020

Personalized cancer treatment and the myth of KRAS wild-type colon tumors

1 reference

12 December 2020

Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE)

1 reference

12 December 2020

Targeting angiogenesis and tumor microenvironment in metastatic colorectal cancer: role of aflibercept.

1 reference

12 December 2020

Reintroduction of Oxaliplatin Is Associated With Improved Survival in Advanced Colorectal Cancer

1 reference

12 December 2020

Should the results of the new EPOC trial change practice in the management of patients with resectable metastatic colorectal cancer confined to the liver?

1 reference

12 December 2020

10.1007/S11864-015-0333-9

Identifiers

DOI

1 reference

Dimensions Publication ID

2 September 2017

1039753946

0 references

1 reference